HEMATOLOGY

Empowering you with best-in-class services and solutions

COMPREHENSIVE SOLUTIONS

HEMATOLOGIC MALIGNANCY DIAGNOSES YOU CAN TRUST
COMPASS®

COMPASS is a comprehensive and flexible assessment that takes the guesswork out of your oncological bone marrow and blood workups. Receive accurate and actionable diagnoses in a brief (one-page), easy-to-understand correlated report. Physician-directed customization integrates a diverse range of technologies to produce results you can rely on. We assign a dedicated hematopathologist to each patient case to personally manage tests, integrate findings, and provide individualized consultations, all to empower you to provide the best possible care to your patients.

CHART®

CHART enables you to seamlessly map a patient’s progression and response to therapy over time. As a serial correlation between previous COMPASS workups, intervening clinical action, and the current COMPASS workup, CHART enables physicians to accurately determine disease progression, assess response to therapy, and plan effective treatment going forward.

INTEGRATED SOLUTIONS

PRECISE MOLECULAR PROFILES FOR INFORMED CLINICAL DECISIONS
MDS Molecular Profile

As one of the first commercial labs using Next-Generation Sequencing technology, Genoptix provides more precise risk assessments that can make all the difference for your patients’ health. Our novel molecular profile for myelodysplastic syndromes (MDS) provides improved risk stratification beyond the International Prognostic Scoring System (IPSS).1 Oncologists receive a clearer picture of the likelihood of MDS progression to develop a more effective treatment plan.

AML Molecular Profile

Genoptix’s novel AML molecular profile gives oncologists and pathologists a better tool to support informed decisions. Combining Next-Generation Sequencing-based genomic analysis with cytogenetic analysis into a single integrated risk assessment, the profile provides the necessary information to make informed choices. Available alone or integrated as part of COMPASS, this powerful profile can impact your ability to formulate the optimal course of therapy for individual patients.

Myeloid Molecular Profile

Based on current consensus guidelines, molecular evidence of a clonal process may be utilized as a diagnostic criterion for patients with suspected MDS.2,3,4 Genoptix’s 40-gene Myeloid Molecular Profile can aid in establishing evidence of a clonal process—an important step in the diagnostic evaluation of MDS. The Myeloid Molecular Profile can also aid in establishing a differential diagnosis by identifying mutations in key genes that may favor related myeloid neoplasms or possible mimics of MDS. This novel assay is available alone or can be integrated into COMPASS, whereby a dedicated hematopathologist with extensive experience, training, and expertise will incorporate results from the Myeloid Molecular Profile into a bone marrow evaluation to provide you a definitive diagnosis.

REFERENCES

  1. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
  2. Valent P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007l31:727-736
  3. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122:2943-2964.
  4. NCCN Practice Guidelines in Oncology, Myelodysplastic Syndromes—Version 2.2014.

CONTACT ME ABOUT HEME